Загрузка...
Tadalafil therapy for sarcoidosis-associated pulmonary hypertension
Abstract. Sarcoidosis-associated pulmonary hypertension (SAPH) is estimated to occur in at least 5% or more of sarcoidosis patients, and it contributes to significant morbidity and mortality. Optimal therapy for SAPH is not well established. We performed a 24-week open-label trial of tadalafil for S...
Сохранить в:
| Опубликовано в: : | Pulm Circ |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
University of Chicago Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5210066/ https://ncbi.nlm.nih.gov/pubmed/28090299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/688775 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|